Santen Pharmaceutical (OTCMKTS:SNPHY) Reaches New 52-Week High – Time to Buy?

Posted by Stanley Muller on Jun 25th, 2026

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) shares reached a new 52-week high on Thursday . The company traded as high as $13.10 and last traded at $13.10, with a volume of 718 shares trading hands. The stock had previously closed at $12.31.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of “Hold”.

Get Our Latest Analysis on SNPHY

Santen Pharmaceutical Price Performance

The business has a fifty day moving average price of $11.50 and a 200 day moving average price of $11.10. The company has a market capitalization of $4.22 billion and a price-to-earnings ratio of 0.10.

About Santen Pharmaceutical

(Get Free Report)

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.